NCT07003035

Brief Summary

The purpose of this study is to evaluate the clinical benefits of personalized total knee arthroplasty (TKA) in comparison with conventional TKA. The study aims to assess surgical outcomes, functional recovery, complication rates, and cost-effectiveness in a multi-center, prospective cohort study.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for all trials

Timeline
18mo left

Started Jun 2025

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress40%
Jun 2025Dec 2027

First Submitted

Initial submission to the registry

March 18, 2025

Completed
3 months until next milestone

Study Start

First participant enrolled

June 1, 2025

Completed
3 days until next milestone

First Posted

Study publicly available on registry

June 4, 2025

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2027

Last Updated

June 4, 2025

Status Verified

May 1, 2025

Enrollment Period

2.6 years

First QC Date

March 18, 2025

Last Update Submit

May 25, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Knee Society Score (KSS)

    The Knee Society Score is a standardized assessment tool to evaluate pain, range of motion, and functional ability following total knee arthroplasty. It includes two sub-scores: a clinical knee score and a functional score. Each sub-score ranges from 0 to 100, with higher scores indicating better outcomes.

    At baseline, 6 months, and 12 months post-surgery

Secondary Outcomes (7)

  • Pain Severity - Visual Analog Scale (VAS)

    At baseline, 6 months, and 12 months post-surgery.

  • Pain Severity - Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)

    At baseline, 6 months, and 12 months post-surgery

  • Functional Improvement - SF-36 Health Survey

    At baseline, 6 months, and 12 months post-surgery.

  • Functional Improvement - Knee Injury and Osteoarthritis Outcome Score (KOOS)

    At baseline, 6 months, and 12 months post-surgery

  • Functional Improvement - Gait Analysis

    At baseline, 6 months, and 12 months post-surgery

  • +2 more secondary outcomes

Study Arms (1)

Cohort 1

A total of 80 participants will be enrolled, with 40 receiving personalized total knee arthroplasty and 40 receiving conventional TKA. Participants will be followed for one year post-surgery to assess clinical outcomes.

Eligibility Criteria

Age50 Years - 80 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

This study will recruit adult patients aged 50-80 years who are undergoing total knee arthroplasty for end-stage knee osteoarthritis or related conditions. Participants will be selected from multiple hospital centers to ensure a diverse patient population.

You may qualify if:

  • Patients aged 50-80 years.
  • Diagnosed with end-stage knee osteoarthritis, post-traumatic arthritis, avascular necrosis, or inflammatory arthritis requiring total knee arthroplasty.
  • Willing and able to provide informed consent.

You may not qualify if:

  • History of prior knee surgery or knee replacement.
  • Severe knee deformity (valgus \>20° or varus \>15°) or instability.
  • Severe contracture (\>25° flexion contracture).
  • Undergoing total knee revision surgery.
  • Rheumatoid arthritis diagnosis.
  • BMI \>35.
  • Neuromuscular disorders affecting knee stability or gait.
  • Pregnancy or lactation.
  • Presence of significant comorbidities posing unacceptable risk, including but not limited to metabolic, renal, hepatic, pulmonary, cardiac, hematologic, neurological, endocrine, infectious, or gastrointestinal conditions.
  • Active or recent severe infections or malignancy.
  • History of drug or alcohol abuse in the past six months.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Beijing Tsinghua Chang Gung Hospital

Beijing, Beijing Municipality, 102218, China

Location

MeSH Terms

Conditions

Osteoarthritis

Condition Hierarchy (Ancestors)

ArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Prof.

Study Record Dates

First Submitted

March 18, 2025

First Posted

June 4, 2025

Study Start

June 1, 2025

Primary Completion (Estimated)

December 31, 2027

Study Completion (Estimated)

December 31, 2027

Last Updated

June 4, 2025

Record last verified: 2025-05

Locations